TP53 and T-cell non-Hodgkin lymphoma: NPM::ALK Hdac1KO tumors displayed augmented promoter accessibility (LFC = 1.52, p = 1.93E-4) (Fig. 6A) and gene expression (LFC = 3.76, adj p = 9.5E-10) of the Jpd2 gene (Fig. 6B), a MYC-collaborating and p53-suppressing factor previously shown to be upregulated in T cell lymphomas that developed as a consequence of loss of HDAC activity [23].